Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
Public ClinicalTrials.gov record NCT04018027. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to severe pruritus.
Study identification
- NCT ID
- NCT04018027
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 401 participants
Conditions and interventions
Conditions
Interventions
- difelikefalin 0.25 mg Drug
- difelikefalin 0.5 mg Drug
- difelikefalin 1.0 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2019 (Actual)
- Primary completion
- Apr 1, 2021 (Actual)
- Completion
- Apr 1, 2021 (Actual)
- Last update posted
- Apr 4, 2022
2019 – 2021
United States locations
- U.S. sites
- 38
- U.S. states
- 20
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cara Therapeutics Study Site | Anniston | Alabama | 36207 | — |
| Cara Therapeutics Study Site | Birmingham | Alabama | 35209 | — |
| Cara Therapeutics Study Site | Scottsdale | Arizona | 85254 | — |
| Cara Therapeutics Study Site | Bryant | Arkansas | 72022 | — |
| Cara Therapeutics Study Site | Fountain Valley | California | 92708 | — |
| Cara Therapeutics Study Site | Lomita | California | 90717 | — |
| Cara Therapeutics Study Site | Cromwell | Connecticut | 06416 | — |
| Cara Therapeutics Study Site | Farmington | Connecticut | 06030 | — |
| Cara Therapeutics Study Site | Aventura | Florida | 33180 | — |
| Cara Therapeutics Study Site 2 | Miami | Florida | 33125 | — |
| Cara Therapeutics Study Site | Miami | Florida | 33174 | — |
| Cara Therapeutics Study Site | Miami Lakes | Florida | 33014 | — |
| Cara Therapeutics Study Site | Ocala | Florida | 34470 | — |
| Cara Therapeutics Study Site | Sarasota | Florida | 34239 | — |
| Cara Therapeutics Study Site | Sweetwater | Florida | 33172 | — |
| Cara Therapeutics Study Site | Columbus | Georgia | 31904 | — |
| Cara Therapeutics Study Site | Boise | Idaho | 83704 | — |
| Cara Therapeutics Study Site 2 | Boise | Idaho | 83713 | — |
| Cara Therapeutics Study Site | Baton Rouge | Louisiana | 70809 | — |
| Cara Therapeutics Study Site | Metairie | Louisiana | 70006 | — |
| Cara Therapeutics Study Site | New Orleans | Louisiana | 70115 | — |
| Cara Therapeutics Study Site | Brighton | Massachusetts | 02135 | — |
| Cara Therapeutics Study Site 2 | Las Vegas | Nevada | 89119 | — |
| Cara Therapeutics Study Site | Berlin | New Jersey | 08009 | — |
| Cara Therapeutics Study Site | Horseheads | New York | 14845 | — |
| Cara Therapeutics Study Site | New York | New York | 10016 | — |
| Cara Therapeutics Study Site | New York | New York | 10023 | — |
| Cara Therapeutics Study Site | Cleveland | Ohio | 44122 | — |
| Cara Therapeutics Study Site | Oklahoma City | Oklahoma | 73118 | — |
| Cara Therapeutics Study Site | Tulsa | Oklahoma | 74136 | — |
| Cara Therapeutics Study Site | Medford | Oregon | 97504 | — |
| Cara Therapeutics Study Site | Rapid City | South Dakota | 57702 | — |
| Cara Therapeutics Study Site 2 | Austin | Texas | 78745 | — |
| Cara Therapeutics Study Site | Austin | Texas | 78759 | — |
| Cara Therapeutics Study Site | Cypress | Texas | 77433 | — |
| Cara Therapeutics Study Site | Dallas | Texas | 75225 | — |
| Cara Therapeutics Study Site | Salt Lake City | Utah | 84117 | — |
| Cara Therapeutics Study Site | Richmond | Virginia | 23226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04018027, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2022 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04018027 live on ClinicalTrials.gov.